<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735072</url>
  </required_header>
  <id_info>
    <org_study_id>GA9001DE</org_study_id>
    <nct_id>NCT00735072</nct_id>
  </id_info>
  <brief_title>Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure</brief_title>
  <official_title>Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>amfAR, The Foundation for AIDS Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many people with HIV fail to regain normal CD4 counts despite effectively suppressing HIV
      replication with medications. Blocking the &quot;co-receptor&quot; for HIV might decrease inflammation
      of the immune system, potentially providing an immune benefit. The goal of the current trial
      is to determine whether adding maraviroc, a new CCR5 &quot;co-receptor&quot; blocker, decreases
      inflammation, providing an immune benefit for patients with low CD4 counts despite
      undetectable viral loads on HIV medications.

      In this study, HIV-infected patients who are receiving antiretroviral therapy for HIV will
      receive either maraviroc or a placebo (sugar pill) each day for 24 weeks. After 24 weeks, the
      study medication will be stopped and all subjects will be followed for 12 more weeks. Blood
      tests measuring the extent of inflammation, low-level viremia, and immune function will be
      measured throughout the trial and compared between treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our primary hypothesis is that CCR5 inhibitors may have protective immunomodulatory effects
      independent of their impact on HIV replication. Specifically, we predict that maraviroc will
      reduce the persistent T cell activation that prevents normal immune reconstitution during
      HAART-mediated viral suppression. This hypothesis will be tested in the context of a placebo
      controlled pilot study assessing the impact of maraviroc in antiretroviral-treated patients
      with a CD4+ T cell count less than 350 cells/mm3. In order to address the immunologic
      activity of this drug independent of plasma HIV RNA levels, we will study individuals who
      have undetectable viral loads (&lt; 75 copies RNA/mL). Subjects will be randomized to maraviroc
      for 24 weeks or matching placebo for 24 weeks, followed by a 12 week washout period. We will
      use as our primary endpoint the proportion of CD8+ T cells that co-expresses CD38 and HLA-DR,
      as these outcomes have been well validated in prior studies. The primary outcome will be
      change in the percentage of activated CD8+ T cells at week 24. Change in CD4+ T cell counts,
      HIV RNA levels (using ultra-sensitive techniques), and other more experimental immunologic
      measurements will be assessed as secondary outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Week 24 Change in Percentage of CD8+ T Cells That Co-express CD38 and HLA DR (Week 24 %CD38+HLA-DR+ CD8+ T Cells Minus Baseline %CD38+HLA-DR+ CD8+ T Cells)</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ T Cell Count</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ultra-sensitive Plasma HIV RNA Level (Single Copy/ml Assay)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brachial Artery Flow-mediated Dilatation (UCSF Site Only)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gut-associated Lymphoid Tissue HIV RNA Level (UCSF Site Only)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maraviroc (dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo for Maraviroc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.</description>
    <arm_group_label>Maraviroc</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western
             blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA,
             or a second antibody test by a method other than ELISA is acceptable as an alternative
             confirmatory test.

          2. Stable antiretroviral therapy for at least 12 months

          3. Screening CD4+ T cell count below 350 cells/mm3

          4. All available CD4+ T cell counts in the last year and at screening &lt; 350 cells/mm3

          5. Screening plasma HIV RNA levels below level of detection (&lt; 50 copies RNA/mL using
             Roche Amplicor or &lt; 75 copies/mL using Bayer bDNA)

          6. All available plasma HIV RNA levels within past year below the level of detection.
             Isolated values that are detectable but &lt; 500 copies will be allowed as long as the
             plasma HIV RNA levels before and after this time point are undetectable.

          7. &gt; 90% adherence to therapy within the preceding 30 days, as determined by self-report.

          8. Both male and female subjects are eligible. Females of childbearing potential must
             have a negative serum pregnancy test at screening and agree to use a double-barrier
             method of contraception throughout the study period.

          9. Ability and willingness of subject or legal guardian/representative to provide
             informed consent

        Exclusion Criteria:

          1. Increase in CD4 count of &gt; 100 cells/mm3 in past year.

          2. Patients who are intending to modify antiretroviral therapy in the next 24 weeks for
             any reason.

          3. Serious illness requiring hospitalization or parental antibiotics within preceding 3
             months.

          4. Concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory
             drug in past 16 weeks.

          5. HBVsAg+ or active hepatitis C or hepatitis B which will require treatment in the
             subsequent 24 weeks.

          6. Prior exposure to CCR5 inhibitors

          7. Screening absolute neutrophil count &lt;1,000 cells/mm3, platelet count &lt;50,000
             cells/mm3, hemoglobin &lt; 8mg/dL, estimated creatinine clearance &lt;40 mL/minute.

          8. Pregnant or breastfeeding women

          9. Use of both Tenofovir and Didanosine in current antiretroviral therapy regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter W Hunt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven G Deeks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy Shulman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Shafer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Lederman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Toyin Adeyemi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco - San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University - Stroger Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <results_first_submitted>June 5, 2011</results_first_submitted>
  <results_first_submitted_qc>June 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2012</results_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>T cell activation</keyword>
  <keyword>Antiretroviral Therapy</keyword>
  <keyword>CCR5</keyword>
  <keyword>Maraviroc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the HIV clinics at San Francisco General Hospital, Stanford University, Case Western Reserve University, and Rush University/CORE Center between September, 2008, and December, 2009.</recruitment_details>
      <pre_assignment_details>All 45 enrolled patients were assigned to study intervention. We over-enrolled by 3 subjects given 2 premature treatment discontinuations and one subject with unavailable baseline peripheral blood mononuclear cell (PBMC) samples available for analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Maraviroc</title>
          <description>Maraviroc (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>interrupted study med during ARV change</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject interrupted ARVs (non-adherence)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Maraviroc</title>
          <description>Maraviroc (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="8"/>
                    <measurement group_id="B2" value="50" spread="10"/>
                    <measurement group_id="B3" value="50" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4+ T Cell Count</title>
        <time_frame>Week 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ultra-sensitive Plasma HIV RNA Level (Single Copy/ml Assay)</title>
        <time_frame>Week 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Brachial Artery Flow-mediated Dilatation (UCSF Site Only)</title>
        <time_frame>Week 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gut-associated Lymphoid Tissue HIV RNA Level (UCSF Site Only)</title>
        <time_frame>Week 24</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Week 24 Change in Percentage of CD8+ T Cells That Co-express CD38 and HLA DR (Week 24 %CD38+HLA-DR+ CD8+ T Cells Minus Baseline %CD38+HLA-DR+ CD8+ T Cells)</title>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc</title>
            <description>Maraviroc (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).</description>
          </group>
        </group_list>
        <measure>
          <title>Week 24 Change in Percentage of CD8+ T Cells That Co-express CD38 and HLA DR (Week 24 %CD38+HLA-DR+ CD8+ T Cells Minus Baseline %CD38+HLA-DR+ CD8+ T Cells)</title>
          <units>%CD38+ HLA-DR+ CD8+ T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="-0.6" upper_limit="4.1"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-3.5" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there will be no difference in the week 24 change in %activated CD8+ T cells between arms. Assuming a standard deviation as high as 3.5% and a Type I error of 5%, with 21 subjects in each treatment arm we would have 80% statistical power to detect a mean 3 percentage-point difference in the percent of activated CD8+ T cells between the active drug and placebo groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Maraviroc</title>
          <description>Maraviroc (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Indirect Hyperbilirubinemia (on atazanavir-based ART)</sub_title>
                <description>All cases were comparable to baseline values and all were on atazanavir-based regimens. None required treatment change during the trial.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>HBV flare, transaminitis</sub_title>
                <description>Subject stopped all ARVs and study medications due to a lapse in insurance coverage (and didnt notify physician or study team). Had a recurrence of HBV viremia with transaminitis (after discontinuing study medication), resolved after restarting ART.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Prolonged Fever</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unexplained fever for 2 weeks without identifiable cause, resolved in absence of any specific therapy and subject had continued study medication without recurrence.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Triglyceride Elevation</sub_title>
                <description>Grade 3 trygliceride elevation noted, comparable to recent values prior to enrollment and resolved to baseline values without change in therapy.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter W. Hunt, MD</name_or_title>
      <organization>UCaliforniaSF</organization>
      <phone>(415) 476-4082 ext 345</phone>
      <email>phunt@php.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

